PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE
100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:
Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.
Evidence
HR+ HER2- Early Breast Cancer (EBC) Patients ≥70 with High Risk 70-gene Signature Benefit from (Neo)adjuvant Chemotherapy (CT): Real World FLEX Study
Publication: SABCS 2025, Presentation ID: PS3-08-17 Authors: Mahtani et al. Title: HR+ HER2- Early Breast Cancer (EBC) Patients ≥70 with High Risk 70-gene Signature Benefit from (Neo)adjuvant Chemotherapy (CT): Real World FLEX Study Introduction: Women ≥ 70 years of age are less likely to receive chemotherapy (CT) due to Read More
70-Gene Signature High Risk Classification Provides Stronger Prognostic Value Than Histologic Grade in HR+HER2– Early Breast Cancer
Publication: SABCS 2025, Presentation ID: PS5-04-19 Authors: Cobain et al. Title: Improved 3-year IDFS with anthracycline-based therapy for patients with 70-gene signature High 2, Luminal B, HR+HER2- early-stage breast cancer Introduction: Pivotal trials of immunotherapy and CDK4/6 inhibitors in early-stage hormone-receptor positive (HR+) HER2 negative (HER2–) breast cancer have Read More
Improved 3-Year IDFS With Anthracycline-Based Therapy for Patients With 70-Gene Signature High 2, Luminal B, HR+HER2- Early-Stage Breast Cancer
Publication: SABCS 2025, Presentation ID: PS2-07-03 Authors: O’Shaugnessy et al. Title: Improved 3-year IDFS with anthracycline-based therapy for patients with 70-gene signature High 2, Luminal B, HR+HER2- early-stage breast cancer Introduction: ABC trials found no significant differences in outcomes among patients with clinically high-risk HR+, HER2- breast cancer when Read More
Leveraging Real-World Evidence To Personalize Adjuvant Therapy in HR+/HER2- Early Breast Cancer
Publication: JNCI Cancer Spectrum, 2025, 9(5), pkaf092 Authors: Yael Bar, MD, PhD , Steven J. Isakoff , MD, PhD , Seth A. Wander , MD, PhD Title: Leveraging real-world evidence to personalize adjuvant therapy in HR+/HER2- early breast cancer Abstract: The use of gene expression assays (GEAs) to assess Read More
MammaPrint Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer: FLEX Registry Real-World Data
Publication: JNCI Cancer Spectrum, August 2025 Authors: Brufsky et al. Title: MammaPrint Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer: FLEX Registry Real-World Data Abstract Background: Gene expression assays help personalize adjuvant chemotherapy decisions for hormone receptor-positive, HER2-negative (HR+HER2-) early breast cancer (EBC). The 70-gene risk of distant-recurrence signature, MammaPrint, Read More
Personalized Neoadjuvant Strategy Using 70-Gene Assay To Increase Breast-Conserving Surgery in ER+/HER2– Breast Cancer
Publication:NPJ Breast Cancer, 20 June 2025 Authors: W. Han, et al. Title: Personalized neoadjuvant strategy using 70-gene assay to increase breast-conserving surgery in ER+/HER2– breast cancer Abstract We investigated whether tailored neoadjuvant therapy (chemotherapy [NCT] or endocrine therapy [NET]) guided by a 70-gene assay could improve breast-conserving surgery (BCS) Read More
Clinicopathologic and Molecular Characterization of Low-Grade, Early-Stage, and HER2-Positive Invasive Breast Carcinoma
Publication: American Journal of Clinical Pathology, 2025, Vol. 163, No. 6Authors: Natasha Hunter, MD; Lisa Han, MD; Haley Corbin, MD; Eric Q. Konnick, MD, MS, ; William R. Gwin III, MD; Shaveta Vinayak, MD; Hannah Linden, MD; William Audeh, MD; Lavanya Samraj, MD, MS; Andrea R. Menicucci, PhD; FLEX Investigators Read More
